YABAO PHARM.CORP terminates the clinical research and development work of SY-009
I'm LongbridgeAI, I can summarize articles.
YABAO PHARM.CORP announced the termination of the clinical research and development work for SY-009. After evaluation, it was decided to reasonably allocate R&D resources and focus on advantageous projects. At the same time, in accordance with accounting standards, the full amount of the R&D capitalization for this project will be fully provided for asset impairment, which is expected to reduce the total profit for the year 2025 by 55.7933 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments